ATLAS (AltaValve) Pivotal Trial
Key facts
- Who runs it
- 4C Medical Technologies, Inc.
- Where
- Ann Arbor, Atlanta, Baltimore, Boston, Charlotte, Charlottesville, Cleveland, Columbia, Detroit, Greenville, Houma, Houston, Jacksonville, Kansas City, La Jolla, Los Angeles, Minneapolis, Morristown, Naples, New York, Oklahoma City, Orange, Phoenix, Portland, Rochester, Royal Oak, San Francisco, Sarasota, Seattle, St Louis, The Bronx, Thousand Oaks, and Tucson, United StatesSee the 36 sitesAlso in 6 other countries, 22 sites
- Trial code
- Status
- Recruiting
- People taking part
- 450 people, planned
- Started
- 3 Sept 2024
- Expected to end
- Sept 2031
- Type of study
- Interventional, 2 groups
- Treatments tested
- AltaValve System.
- Record updated
- 3 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age ≥ 18 years
- Symptomatic New York Heart Association (NYHA) class II-IV
- Moderate-to-severe or severe MR (3+) despite optimal guideline-directed medical therapy (GDMT) as determined by an independent Echo Core Lab
- Unsuitable for surgery and Transcatheter Edge-toEdge Repair (TEER) as determined by the local site Heart Team
Who cannot take part
- Currently enrolled in any other pre-approval investigational trial (does not apply to long-term post-market trials unless these trials might clinically interfere with the current trial endpoints (e.g., limit use of trial-required medication, etc.))
- Concurrent medical condition with a life expectancy of less than 12 months
- Transcatheter aortic repair or replacement within 90 days prior to the baseline required tests
- Percutaneous coronary intervention (PCI) within 30 days prior to the index procedure
- Inability to understand the trial or a history of non-compliance with medical advice
- History of any cognitive or mental health status that would interfere with participation in the trial
- Known hypersensitivity or contraindication to heparin, or warfarin without adequate alternative medications
- Known hypersensitivity to nitinol (i.e., nickel allergy) that cannot be adequately medicated
- Known hypersensitivity to contrast media that cannot be adequately medicated
- Evidence of current left ventricular ejection fraction (LVEF) ≤ 25%
- Inability to provide signed Informed Consent Form (ICF)
- Female subjects who are pregnant or planning to become pregnant within the trial period
Where in United States
Also in 6 other countries, 22 sites
- University of MichiganAnn Arbor, United StatesContact: Steven BollingTaking people
- Wellstar Center for Cardiovascular CareAtlanta, United StatesContact: Nabil SabbakTaking people
- MedStar Health Research Institute, Inc.Baltimore, United StatesContact: Brian BetheaTaking people
- Beth Israel Deaconess Medical CenterBoston, United StatesContact: Roger LahamTaking people
- The Charlotte-Mecklenburg Hospital; Atrium HealthCharlotte, United StatesContact: Michael RinaldiTaking people
- University of VirginiaCharlottesville, United StatesContact: John SaxonTaking people
- Cleveland Clinic FoundationCleveland, United StatesContact: Rishi PuriTaking people
- University Hospitals Cleveland Medical Center*Cleveland, United StatesContact: Guilherme AttizzaniTaking people
- MedStar Health Research Institute, IncColumbia, United StatesContact: Ron WaksmanTaking people
- Henry Ford HospitalDetroit, United StatesContact: Brian O'NeilTaking people
- East Carolina Heart Institute at East Carolina UniversityGreenville, United StatesContact: Paul MahoneyTaking people
- Cardiovascular Institute of the SouthHouma, United StatesContact: Peter Fail, MDTaking people
- The University of Texas Health Science Center at HoustonHouston, United StatesContact: Sukhdeep BasraTaking people
- Baptist Medical CenterJacksonville, United StatesContact: Siddharth WayagankarTaking people
- Saint Luke's Hospital of Kansas CityKansas City, United StatesContact: Adnan ChhatriwallaTaking people
- Scripps HealthLa Jolla, United StatesContact: Curtiss StinisTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Raj MakkarTaking people
- Minneapolis Heart Institute FoundationMinneapolis, United StatesContact: Vinayak BapatTaking people
- AHS Hospital Corp.Morristown, United StatesContact: Phillippe GenereuxTaking people
- NCH Healthcare SystemNaples, United StatesContact: Robert CubedduTaking people
- New York Presbyterian Hospital-Columbia University Medical CenterNew York, United StatesContact: Susheel KodaliTaking people
- South Oklahoma Heart Research LLCOklahoma City, United StatesContact: Naeem TahirkheliTaking people
- Orange County Heart Institute & Research CenterOrange, United StatesContact: Brian KolskiTaking people
- Abrazo Arizona Heart HospitalPhoenix, United StatesContact: Timothy ByrneTaking people
- Banner University Medical CenterPhoenix, United StatesContact: Paul SorajjaTaking people
- Dignity Health St Joseph's Hospital and Medical CenterPhoenix, United StatesContact: Hursh NaikTaking people
- Oregon Health Science UniversityPortland, United StatesContact: Firas ZahrTaking people
- Mayo ClinicRochester, United StatesContact: Charanjit RihalTaking people
- William Beaumont HospitalRoyal Oak, United StatesContact: Amr AbbasTaking people
- Sutter Bay HospitalsSan Francisco, United StatesContact: David DanielsTaking people
- Sarasota Memorial Health Care SystemSarasota, United StatesContact: Ricardo YaryuraTaking people
- University of WashingtonSeattle, United StatesContact: James McCabeTaking people
- Washington UniversitySt Louis, United StatesContact: Alan ZajariasTaking people
- Montefiore Medical CenterThe Bronx, United StatesContact: Mohamed Azeem LatibTaking people
- Los Robles Hospital & Medical CenterThousand Oaks, United StatesContact: Saibal KarTaking people
- TMC HealthcareTucson, United StatesContact: Thomas WaggonerTaking people
About the trial
What the trial wants to find out
This is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatment of mitral regurgitation in a targeted patient population.
The 2 groups in the trial
- Primary CohortTreatment being tested
Designed to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population without at least moderate mitral annular calcification (MAC).
Treatment: AltaValve System.
- Mitral Annular Calcification Cohort (MAC)Treatment being tested
Designed to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population with moderate to severe MAC.
Treatment: AltaValve System.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ATLAS (A Transseptal Left Atrial System for Treatment of Mitral Regurgitation) Pivotal Trial
- Record updated
- 3 August 2026